Tokyo, Feb 22, 2013 (JCN) - Otsuka Pharmaceutical Co., Ltd. announced the launch of 'Neupro Patch' (chemical name: rotigotine) for both the treatment of Parkinson's disease and Restless Legs Syndrome in Japan, beginning on February 26, 2013.
Neupro Patch is the only transdermal dopamine agonist system available in the world, which only needs to be applied once a day, enabling a clinically-effective blood drug concentration via stable drug delivery throughout a 24-hour period.
Approximately 140,000 Parkinson's disease patients are estimated to be living in Japan, and those with progressive disease are more likely to experience drug efficacy diminishing or ceasing during certain times of the day, and as a result their daily living activities are affected.
These patients often experience the difficulty and inconvenience of drug efficacy diminishing or ceasing during late evening or early in the morning, manifesting their symptoms. As a result, patients are often sleep-deprived, which further affects their performance the following morning.
Patients often find it distressing not being able to spend their mornings actively, since even basic activities such as going to the toilet, getting dressed, and taking meals, are affected.
Neupro Patch is expected to provide relief for both patients and their caregivers, as it needs to be applied only once daily in order to achieve a stable blood drug concentration for 24 hours.
Restless Legs Syndrome is characterized by abnormal sensations, particularly in patients' calves, thighs and feet. Patients are not able to stay still due to these unpleasant sensations which are often expressed as creeping, itchy, or prickly feelings within or around the legs, although the expression varies from patient to patient. These sensations are felt at rest in the evening, such as at bedtime, and are known to prevent sound sleep.
Patients with Restless Legs Syndrome may also suffer when sedentary during daytime hours as well. Neupro Patch can alleviate Restless Legs Syndrome symptoms throughout the day via simple application of a once-a-day patch which delivers a stable dopaminergic treatment lasting for 24 hours.
Otsuka Pharmaceutical acquired in 2002 the exclusive rights for developing and marketing Neupro Patch in Japan. Outside of Japan, the drug is known as Neupro, marketed in 35 countries by the product's owner, UCB, the global biopharmaceutical company based in Belgium.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome
(Feb 22, 2013)
|
|
|
Pocari Sweat Launches in Vietnam
(Aug 1, 2012)
|
|
|
Otsuka Pharmaceutical, UCB to Focus Collaboration on Central Nervous System Disorders
(Jan 19, 2012)
|
|
|
Iwamoto Becomes Otsuka Pharmaceutical President
(June 26, 2008)
|
|
|
Otsuka Pharm. to Acquire 49 Pct of French Beverage Maker Alma
(May 28, 2008)
|
|
|
Otsuka to Pay 4 M. Dollars to Settle Off-Label Charges in U.S.
(Mar 28, 2008)
|
|
|
Bristol-Myers Squibb and Otsuka Pharmaceutical Announce Exclusive Licensing Agreement for Diabetes compund Saxagliptin in Japan
(Dec 27, 2006)
|
|
|
Otsuka Pharmaceutical and Chugai Pharmaceutical Announce Antiplatelet Agent Pletaal(R) Co-Promotion Agreement
(Dec 12, 2006)
|
|
|
Otsuka to Release Oral Vasopressin V2-receptor Antagonist Drug
(Oct 12, 2006)
|
|
|
Otsuka Pharmaceutical Factory to Introduce New Nutritional Infusion B-Fluid
(June 13, 2006)
|
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Medical news...
|
|
